Previous 10 | Next 10 |
2023-07-24 08:34:47 ET Kodiak Sciences ( KOD ) -53% announces topline results from its phase 3 Studies of tarcocimab tedromer in Neovascular age-related macular degeneration and diabetic macular edema. Contango Ore ( CTGO ) -25% . 22nd Century Group ( XXII ...
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of this week – YCANTH™ is now the first FDA-approved treatment for molluscum, a highl...
2023-07-21 17:17:13 ET Gainers: Gritstone bio ( GRTS ) +4.8% . LexinFintech Holdings ( LX ) +4.3% . AppLovin ( APP ) +2.9% . Latham Group ( SWIM ) +2.6% . Accuray ( ARAY ) +2.5% . Losers: ALX Oncology Holdings ( ALXO ...
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination product administered by a healthcare professional; Verrica plans to make...
2023-07-14 15:00:24 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Ve...
2023-05-26 17:10:53 ET Gainers: Lexicon Pharmaceuticals ( LXRX ) +14% . Sonos ( SONO ) +4% . Sportsman's Warehouse Holdings ( SPWH ) +4% . Stagwell ( STGW ) +3% . Everbridge ( EVBG ) +3% . Losers: Presto Automation ...
WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Ve...
2023-05-09 08:50:12 ET Verrica Pharmaceuticals press release ( NASDAQ: VRCA ): Q1 GAAP EPS of -$0.15 beats by $0.05 . Revenue of $0.03M (-92.5% Y/Y) misses by $0.61M . For further details see: Verrica Pharmaceuticals GAAP EPS of -$0.15 beats by $0.05, rev...
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten Offering VP-315 Advanced into Part ...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...